News
Latest news.
IDL Biotech includes additional clinics in its ongoing multicenter study for UBC® Rapid in Sweden.
IDL Biotech currently has a number of ongoing clinical studies both internationally and in Sweden, with the aim of demonstrating the clinical benefit of UBC® Rapid in bladder cancer and having the test included as a complement in the follow-up of patients with bladder...
IDL Biotech signs distributor agreements in Rwanda, South Sudan and Somalia
IDL Biotech continues to expand in Africa. Today, IDL Biotech has signed a distributor agreement with Roi Scientific Ltd covering Rwanda, South Sudan and Somalia. The agreement covers the sale of TUBEX® TF. Since its launch in Africa, the company has focused on...
CEO, Anders Hultman, Commenting on FDA delay due to Covid-19
This weekend the US Food and Drug Administration (FDA) has informed that the impact of the COVID-19 pandemic and the reallocation of staff is leading to an even greater prolonged timeline for reviews of submissions. Anders Hultman, CEO of AroCell, commenting the FDA...
IDL Biotech continues its work on automating the TPS® tumor marker
As previously informed, at the end of 2019, IDL Biotech signed a cooperation agreement with the Chinese company Zecen Biotech, regarding automation of the tumor marker TPS® on all Zecen Biotech's instruments. The development project has proceeded very well and the...
Commenting CEO Transition, interview by Redeye
(In Swedish)
IDL Biotech licenses its manual ELISA tumor marker product line to Beckman Coulter Diagnostics
IDL Biotech wants to focus on rapid diagnostic tests and automated assays of its tumor markers. By licensing the platform ELISA to Beckman Coulter, we can focus our resources on streamlining and developing the other platforms, said Gunnar Wahlberg, CEO of IDL...
IDL Biotech develops rapid test for breast cancer
In recent years IDL Biotech has been working on developing a rapid test to detect lung cancer, under the project name MonoTotal® Rapid. However, further development will instead focus on creating a rapid test for breast cancer. Read the article here (Swedish)
AroCell TK 210 ELISA can now be used on automated platforms
Quantification of Thymidine Kinase 1 in serum with AroCell TK 210 ELISA is now validated for use on an open automation platform for ELISA. This enhances the application and use of the assay. We have now validated AroCell TK 210 ELISA for use on an automation platform,...
IDL Biotech is planning for clinical studies in the United States of America for its rapid diagnostic test for bladder cancer, UBC® Rapid.
In 2019, IDL Biotech submitted a so-called Pre-submission request to the US FDA (United States Food and Drug Administration) this was done to ensure the future approval of UBC® Rapid, the companys rapid diagnostic test for bladder cancer. As of now, the company is...
